Safety and Immunogenicity of V920 Ebola Vaccine in Healthy Adults

Phase 1, randomised, double-blind trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (4 cohorts), sponsored by Merck & Co. Primary endpoints: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events at 14 days, Number of Participants With One or More Solicited Systemic Treatment-Emergent Adverse Events at 14 days and 2 more. Started Oct 2014; status: completed.